PaySign: Canaccord Genuity downgrades on lower visibility of core businesses

Paysign

23/12/2020 10:01

** Canaccord Genuity downgrades payment solution provider's
shares  PAYS.O  to "hold" from "buy"; lowers PT to $5 from $9
    ** Brokerage says COVID-19's negative impact on plasma
donation volume will persist, coupled with long-term trends such
as decreasing plasma collections and revenue per center
    ** PaySign is a provider of prepaid debit cards that operate
primarily in the plasma and pharma industry  
    ** Shift in pharma business towards new patient
affordability solutions and medical service providers could
cause uncertainity in top-line metrics - Canaccord 
    ** 2 of 5 brokerages rate the stock "buy" or higher, 2
"hold" and 1 "sell" or lower; median PT is $5.5 - Refinitv Data
    ** Up to last close, PAYS down 51.6% YTD

 (Reporting by Siddarth S)
 ((Siddarth.s@thomsonreuters.com;))